- Home
- SLGL vs NRXS Comparison
SLGL vs NRXS Comparison
Compare SLGL & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- NRXS
- Stock Information
- Founded
- SLGL 1997
- NRXS 2011
- Country
- SLGL Israel
- NRXS United States
- Employees
- SLGL N/A
- NRXS N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- SLGL Health Care
- NRXS
- Exchange
- SLGL Nasdaq
- NRXS Nasdaq
- Market Cap
- SLGL 18.3M
- NRXS 20.3M
- IPO Year
- SLGL 2018
- NRXS 2023
- Fundamental
- Price
- SLGL $0.52
- NRXS $3.03
- Analyst Decision
- SLGL Strong Buy
- NRXS
- Analyst Count
- SLGL 2
- NRXS 0
- Target Price
- SLGL $5.00
- NRXS N/A
- AVG Volume (30 Days)
- SLGL 68.5K
- NRXS 25.3K
- Earning Date
- SLGL 11-15-2024
- NRXS 11-12-2024
- Dividend Yield
- SLGL N/A
- NRXS N/A
- EPS Growth
- SLGL N/A
- NRXS N/A
- EPS
- SLGL N/A
- NRXS N/A
- Revenue
- SLGL $11,707,000.00
- NRXS $2,456,219.00
- Revenue This Year
- SLGL $457.85
- NRXS $383.16
- Revenue Next Year
- SLGL N/A
- NRXS N/A
- P/E Ratio
- SLGL N/A
- NRXS N/A
- Revenue Growth
- SLGL 869.93
- NRXS N/A
- 52 Week Low
- SLGL $0.33
- NRXS $2.00
- 52 Week High
- SLGL $1.58
- NRXS $3.89
- Technical
- Relative Strength Index (RSI)
- SLGL 37.57
- NRXS 56.84
- Support Level
- SLGL $0.40
- NRXS $3.03
- Resistance Level
- SLGL $0.57
- NRXS $3.31
- Average True Range (ATR)
- SLGL 0.06
- NRXS 0.40
- MACD
- SLGL -0.01
- NRXS 0.06
- Stochastic Oscillator
- SLGL 36.50
- NRXS 60.57
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).